Obsidian Therapeutics Inc(OBX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 4 at 7:30 PM ET (Korea 9/5 08:30)
Full metrics table
| Index | - | P/E | 0.1 | EPS (ttm) | 161.87 | Insider Own | 12.41% | Shs Outstand | 61.8M | Perf Week | 3.19% |
| Market Cap | 1.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 54.1M | Perf Month | -40.67% |
| Enterprise Value | 1.34B | PEG | - | EPS next Q | -0.59 | Inst Own | 15.01% | Short Float | 0.07% | Perf Quarter | -11.47% |
| Income | 0.12B | P/S | - | EPS this Y | - | Inst Trans | 0.06% | Short Ratio | 0.61 | Perf Half Y | 110.25% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 78.97% | ROA | 432.24% | Short Interest | 0.04M | Perf YTD | 282.27% |
| Book/sh | -2701.52 | P/C | 30.16 | EPS past 3/5Y | - | ROE | - | 52W High | -66.34% ($49.97) | Perf Year | 368.78% |
| Cash/sh | 0.56 | P/FCF | - | Sales past 3/5Y | - | ROIC | 397.65% | 52W Low | 456.95% ($3.02) | Perf 3Y | -60.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 960.73% | Gross Margin | - | Volatility(W/M) | 12.81% 18.41% | Perf 5Y | -98.96% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.18 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.3 | EPS Q/Q | -10780.55% | Profit Margin | - | RSI (14) | 42.78 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.3 | Sales Q/Q | - | SMA20 | -16.95% ($20.25) | Beta | 2.66 | Target Price | $42.5 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/08/12 | SMA50 | -13.57% ($19.46) | Rel Volume | 2.38 | Prev Close | $17.09 |
| Employees | 3 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | - | SMA200 | 36.57% ($12.32) | Avg Volume(3M) | 0.06M | Price | $16.82 |
| IPO | 2019/11/7 | Option/Short | No/Yes | Trades | 1736 | Volume | 140,115 | Change | -1.58% |
Company
OBX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This is a US clinical-stage biotech company developing cell therapies that arm immune cells harvested from tumors with controllable cytokines. Its lead candidate, based on autologous tumor-infiltrating lymphocytes (TILs), is currently in clinical trials for melanoma and non-small cell lung cancer, and the company internally holds a synthetic biology platform for modulating protein function.
Over the past 1 year, roughly in the middle
66% below its 1-year high.
OBX makes money exceptionally well
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +79.0% this year.
Tap to view numbers
The stock looks undervalued
Trading at 0.1 times earnings.
Tap to view numbers
Results came in about as expected
Generally in line with estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -60.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 15.0%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $1B.
OBX $1B PER 0.1
VRTX $138B PER 31.8
REGN $85B PER 20.5
ARGX $65B PER 39.4
FAQ
What kind of company is OBX?
OBX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OBX?
The market cap of OBX is approximately $1.0B, ranking 2,650 within its sector.
What is the P/E ratio of OBX?
OBX has a P/E ratio of approximately 0.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for OBX?
OBX has recorded a 52-week high of $49.97 and a low of $3.02.
